[{"id":"dde5d7d2-1dad-4eff-ab54-2b67e2cc553a","acronym":"HERKULES-2","url":"https://clinicaltrials.gov/study/NCT04959981","created_at":"2021-12-13T15:11:31.264Z","updated_at":"2024-07-02T16:35:42.103Z","phase":"Phase 1b","brief_title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC","source_id_and_acronym":"NCT04959981 - HERKULES-2","lead_sponsor":"Erasca, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/02/2021","start_date":" 09/02/2021","primary_txt":" Primary completion: 04/27/2023","primary_completion_date":" 04/27/2023","study_txt":" Completion: 04/27/2023","study_completion_date":" 04/27/2023","last_update_posted":"2023-07-25"},{"id":"330ac409-c653-4ffe-b5ad-e37d750b01db","acronym":"HERKULES-4","url":"https://clinicaltrials.gov/study/NCT05279859","created_at":"2022-03-15T18:52:50.830Z","updated_at":"2024-07-02T16:36:08.894Z","phase":"Phase 1b/2","brief_title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05279859 - HERKULES-4","lead_sponsor":"Erasca, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • ERAS-007 • ERAS-601"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-06-15"}]